ABSTRACT
Varicella is a self-limiting and relatively mild disease of childhood, although it is frequently more severe and complicated among the immunocompromised rheumatology patients on immunomodulator therapies. In addition, future reactivation of the dormant virus in dorsal root ganglia may cause herpes zoster infection, which can be very debilitating. In this manuscript, we discuss the nature of this infection along with its potential vaccine especially among rheumatology patients.
Subject(s)
Antirheumatic Agents/adverse effects , Chickenpox Vaccine/adverse effects , Chickenpox/immunology , Immunocompromised Host/immunology , Immunosuppressive Agents/adverse effects , Rheumatic Diseases/immunology , Antirheumatic Agents/therapeutic use , Chickenpox/prevention & control , Chickenpox Vaccine/immunology , Humans , Immunosuppressive Agents/therapeutic use , Rheumatic Diseases/drug therapy , Virus Activation/drug effects , Virus Activation/immunologyABSTRACT
Herpes simplex virus type 1 (HSV-1), also known as herpes labialis, is the etiologic agent of vesicular lesions of the oral mucosa commonly referred to as "cold sores". HSV-1 can also cause clinical disease in a wide variety of other anatomic locations including the genitalia, liver, lung, eye, and central nervous system. These infections can be severe, particularly in the setting of immunosuppression, such as inflammatory arthropathy patients on Methotrexate ± biological therapies. Here, we highlight the importance of physician awareness of HSV due to its potential impact for rheumatology patients.
Subject(s)
Arthritis/drug therapy , Arthritis/pathology , Herpes Labialis/complications , Herpesvirus 1, Human/pathogenicity , Antirheumatic Agents/adverse effects , Arthritis/virology , Herpes Labialis/pathology , Humans , Immunocompromised Host , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Inflammation/drug therapy , Inflammation/pathology , Inflammation/virologyABSTRACT
Alcohol, steroids and cocaine have all been shown to be independent risk factors for osteonecrosis when taken in excess. Here we present a case of a young girl who developed debilitating osteonecrosis secondary to low doses of alcohol, steroids and cocaine. We feel it is important to highlight to those caring for such patients of the potential devastating complication of these three agents.
Subject(s)
Alcoholism/pathology , Cocaine-Related Disorders/pathology , Osteonecrosis/chemically induced , Steroids/adverse effects , Substance-Related Disorders/pathology , Adult , Alcoholism/complications , Ankle/diagnostic imaging , Ankle/pathology , Cocaine-Related Disorders/complications , Female , Humans , Magnetic Resonance Imaging , Osteonecrosis/complications , Osteonecrosis/diagnostic imaging , Radiography , Substance-Related Disorders/complicationsABSTRACT
INTRODUCTION: Human Immunodeficiency Virus (HIV) has an estimated prevalence of 0.9% in India (5.2 million). Anti-retroviral drugs (ARV) are the treatments of choice and non-adherence is an important factor in treatment failure and development of resistance, as well as being a powerful predictor of survival. This study assesses adherence to ARV in HIV positive patients in Bangalore, India, a country where only 10% of those who need therapy are receiving it. METHODS: A cross-sectional anonymous questionnaire survey of 60 HIV antibody positive patients was carried out with patients attending HIV outpatient services at two centres: The Chest and Maternity Centre, Rajajinagar, and Wockhardt Hospital and Heart Institute, Bangalore. Consent was obtained. Translation was done by a translator and doctors where required. Data was analysed using SPSS statistical analysis. RESULTS: A response rate of 88% (53/60) was achieved. The mean patient age was 39.98 years, with 50% aged 30-40, and 73.6% of participants being male. Mean family size was 4.8 (1-13). 21% lived less than 50 kms and 21% greater than 400 kms from clinic.60% reported they were fully adherent. Adherence was statistically significantly linked to regular follow-up attendance (70.5%, p = 0.002). No other results were statistically significant but trends were found. "100% adherence" trends were seen in older patients, male gender, those from larger families, those who had a previous AIDS defining illness, those taking fewer tablets, and without food restrictions. Commonest side-effects causing non-adherence were metabolic reasons (66%) and GI symptoms (50%). No trends were seen for education level, family income, distance travelled to clinic, time since diagnosis, or time on ART. CONCLUSION: Regular attendance for follow up was statistically significant for 100% lifetime adherence. Positive trends were seen in those in larger families, older, those who had AIDS defining illness, simple regimes, and without side-effects. Education, income, distance travelled and length of time diagnosed or treated had no effect on adherence.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Biological Therapy/adverse effects , Clinical Audit , Hotlines , Infections/drug therapy , Nurse Clinicians , Rheumatic Diseases/drug therapy , Drug Administration Schedule , Female , Humans , Infections/epidemiology , Male , Patient Education as Topic , Retrospective Studies , Risk Factors , Self Care , Withholding TreatmentSubject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Antirheumatic Agents/administration & dosage , Health Knowledge, Attitudes, Practice , Immunoglobulin G/administration & dosage , Mental Recall , Receptors, Tumor Necrosis Factor/administration & dosage , Rheumatic Diseases/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Vaccination , Adalimumab , Antibodies, Monoclonal, Humanized/adverse effects , Antirheumatic Agents/adverse effects , Drug Administration Routes , Etanercept , Female , Humans , Immunoglobulin G/adverse effects , Male , Patient Education as Topic , Rheumatic Diseases/diagnosis , Rheumatic Diseases/immunology , Time Factors , Tumor Necrosis Factor-alpha/metabolismSubject(s)
Antibodies, Monoclonal, Murine-Derived/adverse effects , Antirheumatic Agents/adverse effects , Lung Diseases, Interstitial/chemically induced , Lung Diseases, Interstitial/diagnosis , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis/drug therapy , Clarithromycin/therapeutic use , Drug Therapy, Combination , Humans , Hydrocortisone/therapeutic use , Lung Diseases, Interstitial/drug therapy , Male , Middle Aged , Prednisolone/therapeutic use , Rituximab , Treatment OutcomeSubject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Environmental Exposure/adverse effects , Skin Neoplasms/prevention & control , Sunlight/adverse effects , Sunscreening Agents/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Female , Humans , Interviews as Topic , Male , Middle Aged , Pilot ProjectsABSTRACT
Takayasu arteritis is a rare large vessel vasculitis which has traditionally been treated with high-dose steroids. There have been a small number of publications where biological agents have been used to manage refractory cases. To the authors knowledge, there are no publications using biological agents in combination with steroids as a first-line treatment in Takayasu arteritis. In this publication, we document the case of Takayasu arteritis, in a 39-year-old woman, where rituximab was used in combination with steroids as a first-line agent in the setting of poorly controlled bipolar affective disorder.
Subject(s)
Immunosuppressive Agents/therapeutic use , Rituximab/therapeutic use , Takayasu Arteritis/drug therapy , Adult , Female , Humans , Treatment OutcomeSubject(s)
Papillomavirus Infections/prevention & control , Papillomavirus Vaccines , Rheumatic Diseases/etiology , Uterine Cervical Neoplasms/prevention & control , Female , Humans , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/therapy , Lupus Erythematosus, Systemic/virology , Papillomavirus Infections/complications , Papillomavirus Infections/pathology , Rheumatic Diseases/pathology , Rheumatic Diseases/therapy , Uterine Cervical Neoplasms/etiology , Uterine Cervical Neoplasms/pathologySubject(s)
Appointments and Schedules , Patient Satisfaction , Reminder Systems , Rheumatic Diseases , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Data Collection , Female , Humans , Male , Middle Aged , Outpatient Clinics, Hospital , Young AdultSubject(s)
Pregnancy Complications, Infectious/epidemiology , Sexually Transmitted Diseases/epidemiology , Female , Humans , Ireland , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/microbiology , Pregnancy Complications, Infectious/prevention & control , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/microbiology , Sexually Transmitted Diseases/prevention & controlABSTRACT
BACKGROUND: Warfarin is an oral anticoagulant (OAT) that needs active management to ensure therapeutic range. Initial management is often carried out as an inpatient, though not requiring inpatient facilities. This mismatch results in financial costs which could be directed more efficaciously. The extent of this has previously been unknown. Here we aim to calculate the potential number of bed nights which may be saved among those being dose optimized as inpatients and examine associated factors. METHODS: A 6 week prospective audit of inpatients receiving OAT, at Cork University Hospital, was carried out. The study period was from 11th June 2007 to 20th July 2007. Data was collected from patient's medications prescription charts, medical record files, and computerised haematology laboratory records. The indications for OAT, the patient laboratory coagulation results and therapeutic intervals along with patient demographics were analysed. The level of potentially avoidable inpatient nights in those receiving OAT in hospital was calculated and the potential cost savings quantified. Potential avoidable bed nights were defined as patients remaining in hospital for the purpose of optimizing OAT dosage, while receiving subtherapeutic or therapeutic OAT (being titred up to therapeutic levels) and co-administered covering low molecular weight heparin, and requiring no other active care. The average cost of euro638 was taken as the per night hospital stay cost for a non-Intensive Care bed. Ethical approval was granted from the Ethical Committee of the Cork Teaching Hospitals, Cork, Ireland. RESULTS: A total of 158 patients were included in the audit. There was 94 men (59.4%) and 64 women (40.6%). The mean age was 67.8 years, with a median age of 70 years.Atrial Fibrillation (43%, n = 70), followed by aortic valve replacement (15%, n = 23) and pulmonary emboli (11%, n = 18) were the commonest reasons for prescribing OAT. 54% had previously been prescribed OAT prior to current admission.It was confirmed that, there are potentially avoidable nights in patients receiving OAT. The majority of this group were those being commenced on OAT for the first time (p = 0.00002), in the specialities of Cardiology, Cardiothoracic surgery and Care of the Elderly. The potential number of bed nights to be saved is 13 per week for the hospital or 1.1 bed nights per 10,000 general hospital admissions. These were predominantly weekday nights. The estimated cost of avoidable inpatient OAT dose optimization was approximately euro8300 per week. CONCLUSION: With rising costs and the increasing demands for acute hospital beds, alterations to inpatient management for this group of patients should be considered. Alternatives include increasing the size of current anticoagulation clinics, introduction of POCT (point of care testing) devices and increased GP management. POCT can be justified based upon the publication by Gardiner et al, who showed that 87% of patients find self testing straightforward, 87% were confident in the result they obtained using the devices and 77% preferred self testing.
ABSTRACT
Ulcerative colitis (UC), a member of the family of inflammatory bowel disease (IBD), occurs worldwide. It has an incidence which in recent years has been rising in areas such as Southern Europe and Asia, while remaining relatively constant in Northern Europe and North America. Complications associated with UC include toxic dilatation, perforation, carcinoma and massive haemorrhage. Extra-intestinal complications also occur and these include Thromboemboli (TE).Thromboembolic disease has a greater incidence and recurrence rate among patients with IBD than the general population.
ABSTRACT
INTRODUCTION: Takayasu's Arteritis, formerly known as "pulseless disease", is a chronic idiopathic vasculitis which affects the large vessels in the body. First described in the 1800's, this rare condition is more commonly found in Asian women in their 40's. The aorta and its main branches are the primary vessels affected, with the most typical features reflected as ischemia or aneurysm formation. With Takayasu's Arteritis being a rare condition and its acute phase presentation often similar to other conditions, diagnosis is often difficult. CASE PRESENTATION: A 48 year old Irish Caucasian female, who presented as a typical history of an aortic dissection (chest pain radiating to her back in an interscapular region and a systolic blood pressure differential of 50 mmHg between her right and left upper limbs), was investigated with a number of imaging modalities and diagnosed with Takayasu's Arteritis, involving arteries affecting a number of organs. She was treated as per protocol for Takayasu's Arteritis. A diagnosis of cervical cancer quickly followed. CONCLUSION: This case report highlights that a differential diagnosis should never be dispelled based upon a "typical" history. The importance of modern day imaging techniques such as CT, MRI and angiography, can often be paramount to confirming a diagnosis and the extent of the pathology.A possible link between Takayasu's Arteritis and gynaecological malignancies may exist.
ABSTRACT
BACKGROUND: Cervical cancer is increasing at 1.5% per year in Ireland with 50% mortality giving 2.2% of all cancer deaths. In the Mid-West region a pilot screening programme has begun to screen all women 25-60 years. 66% of Genitourinary/Sexually transmitted disease (GU/STD) clinics' abnormal smears are <25 years. Requests to abandon "opportunistic" screening prompted this GU/STD clinic audit. METHODS: 221(8.4%) patients referred to colposcopy over 4 years were audited. Retrospective analysis was carried out on GU/STD clinic files, hospital files and computer records for biopsy reports. Ethical approval was prospectively granted. RESULTS: 2637 smears were carried out from November 1999 - September 2003.221 patients referred to colposcopy were audited.1%, 3%, 5% had severe, moderate and, mild dyskaryosis, respectively, on cervical screening while 0.8%, 1.2%, 1.5% had CIN3, CIN2, CIN1 abnormalities, respectively, on biopsy with 3.5% having no abnormality (Cervical Intraepithelial Neoplasia = CIN).53% referred to colposcopy were <25 years. CONCLUSION: 2% had high grade lesions. 37% of high grade lesions are <25 years.Of the high grade lesions 13% had Chlamydia trachomatis (27% of CIN3) and 44% had HPV despite Relative Risks (RR) being 0.75 and 1.09 respectively. Older women had higher grade changes. No statistical difference was found for progression, regression and persistence in those over and under 25.
ABSTRACT
According to the International Headache Society, idiopathic stabbing headache (ISH), an indomethacin-responsive headache syndrome, is a paroxysmal disorder of short duration manifested as head pain occurring as a single stab or a series of stabs involving the area supplied in the distribution of the first division of the trigeminal nerve. Stabs last for approximately a few seconds, occurring and recurring from once to multiple times per day in an irregular frequency, with no underlying attributable disorder.Previously indomethacin was the principle treatment option for ISH, despite therapeutic failure in up to 35% of cases, until reports showed gabapentin, melatonin and selective cyclo-oxygenase-2 (COX-2) inhibitors were also possibly effective. In this report we present the full case report of an 88 year old lady with a history of untreated ISH where etoricoxib, a selective COX-2 inhibitor, was used to effectively treat her ISH.